Abstract: A fluid collection device comprising a body comprising a capsule interface, and a capsule configured to interface with the body via the capsule interface and configured to hold a sample receiving chip. The sample receiving chip comprises a substrate that receives an aliquot volume of a sample fluid, wherein the substrate is operatively shaped to receive the aliquot volume of sample fluid through capillary action, and a sample region of the substrate, sized such that the volume of the sample fluid is sufficient to operatively cover a portion of the sample region, whereupon energy properties of the sample fluid can be transduced to produce a sample fluid reading.

Abstract: A fluid collection device comprising a body comprising a capsule interface, and a capsule configured to interface with the body via the capsule interface and configured to hold a sample receiving chip. The sample receiving chip comprises a substrate that receives an aliquot volume of a sample fluid, wherein the substrate is operatively shaped to receive the aliquot volume of sample fluid through capillary action, and a sample region of the substrate, sized such that the volume of the sample fluid is sufficient to operatively cover a portion of the sample region, whereupon energy properties of the sample fluid can be transduced to produce a sample fluid reading.

Abstract: An apparatus, system and method are provided for measuring state properties without requiring an internal or proximate power supply. The apparatus provides a sensing device that is responsive to fluctuations in a state property that are encountered within the test zone. Due to the fluctuations experienced by the sensing device, a sensing signal is generated and transmitted to an optical device, such as an interferometer. The sensing signal's affect on the optical device produces an interference pattern that may be detected remotely and correlated to the fluctuation experienced by the sensing device.

Abstract: A fluid collection device comprising a body comprising a capsule interface, and a capsule configured to interface with the body via the capsule interface and configured to hold a sample receiving chip. The sample receiving chip comprises a substrate that receives an aliquot volume of a sample fluid, wherein the substrate is operatively shaped to receive the aliquot volume of sample fluid through capillary action, and a sample region of the substrate, sized such that the volume of the sample fluid is sufficient to operatively cover a portion of the sample region, whereupon energy properties of the sample fluid can be transduced to produce a sample fluid reading.

Abstract: The present invention provides compositions, therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one substituted azetidinone or substituted ?-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.

Abstract: This invention provides for method for the treatment, prevention or ameliorating the symptoms of nonalcoholic fatty liver disease (NAFLD) in a mammal in need thereof comprising the step of administering an effective amount of a composition comprising a therapeutic combination of at least one cholesterol lowering agent and/or at least one H3 antagonist/inverse agonist.

Abstract: The use of azetidinone compounds that are inhibitors of cholesterol absorption as tools for discovering and characterizing proteins involved in trafficking or absorption of cholesterol and/or cholesteryl esters in biological systems is presented These compounds can serve as tools for competitive binding assays to discover and characterize other chemical agents useful as cholesterol absorption inhibitors. New compounds of the present invention are also highly efficacious inhibitors of cholesterol absorption.

Abstract: The present invention is directed to pharmaceutical compositions comprising a sterol absorption inhibitor, a CEPT inhibitor and/or an HMG-CoA reductase inhibitor as well as methods for treating sitosterolemia, hypercholesterolemia, hyperlipidemia, atherosclerosis, mixed dyslopidemia, vascular events prevention and related disorders in a mammal in need thereof by administering said pharmaceutical compositions to the mammal.

Abstract: The present invention provides therapeutic combinations and methods including at least one sterol or 5?-stanol absorption inhibitor that can be useful for treating xanthomas and hypercholesterolemia.

Abstract: The present invention provides compositions, therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one substituted azetidinone or substituted ?-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.

Abstract: The present invention provides methods for the treatment of obesity using sterol or 5?-stanol absorption inhibitors and compositions and therapeutic combinations including sterol or 5?-stanol absorption inhibitors and at least one obesity control medication.

Abstract: The use of azetidinone compounds that are inhibitors of cholesterol absorption as tools for discovering and characterizing proteins involved in trafficking or absorption of cholesterol and/or cholesteryl esters in biological systems is presented. These compounds can serve as tools for competitive binding assays to discover and characterize other chemical agents useful as cholesterol absorption inhibitors. New compounds of the present invention are also highly efficacious inhibitors of cholesterol absorption.

Abstract: The present invention is directed to the use of sterol absorption inhibiting compounds, pharmaceutical compositions thereof, therapeutic combinations and their use in combination with other lipid lowering agents to treat or prevent sitosterolemia and/or to lower the concentration of sterol(s) other than cholesterol in plasma or tissue of a mammal. Methods of treating or preventing vascular disease and coronary events also are provided.

Abstract: A pulsed source of high energy neutrons is used to irradiate the earth formations in the vicinity of a well borehole. Gamma rays produced by the inelastic scattering of the fast neutrons are observed in four energy regions of the gamma ray energy spectrum corresponding to the inelastic scattering of neutrons by carbon, oxygen, silicon and calcium. Signals representative of the carbon/oxygen, calcium/silicon and carbon plus oxygen gamma rays observed are developed. By appropriately combining these signals with a separately derived hydrogen index log the quality of coal bearing formations or oil shale regions penetrated by the borehole may be determined.

Abstract: Methods and apparatus are provided for making improved pulsed neutron derived measurements of the carbon: oxygen ratio in subsurface earth formations. Plural radiation measurements are made as a function of time from the initiation of the neutron pulse to distinguish inelastic and thermal neutron interactions. These measurements are also within their respective time functions, energy dependent. The time and energy dependent radiation measurements are then combined in several different manners to provide an improved carbon: oxygen ratio measurement and multiple porosity and formation lithology indication measurements.